Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;73(8):1311-1332.
doi: 10.1007/s00011-024-01900-w. Epub 2024 Jun 5.

The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review

Shiyu Jin  1 , Sheng Wan  1   2 , Renxue Xiong  1   2 , Yujie Li  1 , Tingru Dong  1 , Cuiping Guan  3   4
Affiliations
Review

The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review

Shiyu Jin et al. Inflamm Res. 2024 Aug.

Abstract

Background: Regulatory T cells (Tregs) play vital roles in controlling immune reactions and maintaining immune tolerance in the body. The targeted destruction of epidermal melanocytes by activated CD8+T cells is a key event in the development of vitiligo. However, Tregs may exert immunosuppressive effects on CD8+T cells, which could be beneficial in treating vitiligo.

Methods: A comprehensive search of PubMed and Web of Science was conducted to gather information on Tregs and vitiligo.

Results: In vitiligo, there is a decrease in Treg numbers and impaired Treg functions, along with potential damage to Treg-related signaling pathways. Increasing Treg numbers and enhancing Treg function could lead to immunosuppressive effects on CD8+T cells. Recent research progress on Tregs in vitiligo has been summarized, highlighting various Treg-related therapies being investigated for clinical use. The current status of Treg-related therapeutic strategies and potential future directions for vitiligo treatment are also discussed.

Conclusions: A deeper understanding of Tregs will be crucial for advancing Treg-related drug discovery and treatment development in vitiligo.

Keywords: CD4+ T cells; CD8+ T cells; Therapy; Tregs; Vitiligo.

PubMed Disclaimer

References

    1. Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621–48. https://doi.org/10.1146/annurev-immunol-100919-023531 . - DOI - PubMed
    1. Bergqvist C, Ezzedine K. Vitiligo: a focus on pathogenesis and its therapeutic implications. J Dermatol. 2021;48(3):252–70. https://doi.org/10.1111/1346-8138.15743 . - DOI - PubMed
    1. Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571–92. https://doi.org/10.1159/000506103 . - DOI - PubMed
    1. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1-13. https://doi.org/10.1111/j.1755-148X.2012.00997.x . - DOI - PubMed - PMC
    1. Ezzedine K, Gauthier Y, Léauté-Labrèze C, Marquez S, Bouchtnei S, Jouary T, et al. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J Am Acad Dermatol. 2011;65(5):965–71. https://doi.org/10.1016/j.jaad.2010.08.031 . - DOI - PubMed

LinkOut - more resources